Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Foradil

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Inhaled Corticosteroids and LABAs In December, the FDA removed the boxed warning on combination products containing an inhaled… Expand
2008
2008
Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI delivery, particularly for COPD patients… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2004
2004
In order to characterize the efficacy of dry powder inhalers, in vitro measurements are much easier to perform than human… Expand
2004
2004
Background: For maximum treatment compliance there is a need to provide asthma patients with devices that suit their particular… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • table 2
Review
2004
Review
2004
Evaluation of patients with chronic obstructive pulmonary disease (COPD) often includes the use of post‐bronchodilator… Expand
2003
2003
This double-blind, randomised, multi-centre, parallel-group study compared the effect of adding Foradil (formoterol fumarate) to… Expand
2002
2002
AbstractObjective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice… Expand
Highly Cited
2001
Highly Cited
2001
Formoterol fumarate is a beta2-agonist bronchodilator that combines a fast onset of action with a long duration of action. Its… Expand
Highly Cited
1999
Highly Cited
1999
AbstractObjective: The pharmacokinetics of the long-acting β2-agonist formoterol fumarate, which is a racemate of the (S,S)- and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
1999
1999
OBJECTIVE The pharmacokinetics of the long-acting beta2-agonist formoterol fumarate, which is a racemate of the (S,S)- and (R,R… Expand